Compare ALCO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | OVID |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 365.5M |
| IPO Year | 1994 | 2017 |
| Metric | ALCO | OVID |
|---|---|---|
| Price | $41.01 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $44.00 | $4.60 |
| AVG Volume (30 Days) | 17.2K | ★ 2.5M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $29.04 | $0.27 |
| 52 Week High | $45.01 | $3.11 |
| Indicator | ALCO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 55.01 |
| Support Level | $39.99 | $2.56 |
| Resistance Level | $41.96 | $3.11 |
| Average True Range (ATR) | 1.04 | 0.15 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 32.55 | 44.83 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.